8-K: MetaVia Doses First Patient in Higher-Dose Obesity Trial

MetaVia Inc. has dosed the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1/glucagon agonist for obesity, evaluating higher dose titration strategies.

Summary

• MetaVia Inc. announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors.
• Part 3 of the trial involves two 16-week titration cohorts designed to assess one-step and two-step dose-escalation strategies to achieve higher target doses and optimize tolerability.
• The trial aims to evaluate doses up to 48 mg (one-step) and 64 mg (two-step) in obese, otherwise healthy adults.
• Previous results at a 48 mg dose showed approximately 9% weight loss, reductions in waist circumference, improved glycemic control, and early signals of liver benefit.
• Data from Part 3 of the Phase 1 trial is expected in the fourth quarter of 2026.
• DA-1726 is being developed for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking progress in a key clinical trial with promising early data, though it remains in an early stage of development.

Positives

• First patient dosed in higher-dose cohorts (Part 3) of the Phase 1 trial for DA-1726.
• Previous results at 48 mg dose showed approximately 9% weight loss.
• Meaningful reductions in waist circumference observed in prior studies.
• Improved glycemic control demonstrated in earlier trials.
• Early signals of direct liver benefit noted.
• Favorable tolerability profile observed.
• Potential for a more streamlined path to optimal dosing compared to current therapies.
• Pre-clinical studies showed DA-1726 improved weight loss compared to semaglutide and similar weight reduction to tirzepatide while consuming more food.

Negatives

• The trial is still in Phase 1, indicating early-stage development.
• MetaVia has a history of net losses.
• The company may need to raise additional capital to fund operations.

Risks

• Risks associated with MetaVia's history of net losses and the sufficiency of its cash on hand.
• The need to raise additional capital.
• Adverse global economic conditions.
• Challenges in executing its commercial strategy.
• Obtaining regulatory approval through development steps.
• Realizing the benefits of the license agreement with Dong-A ST Co. Ltd.
• Cooperation of contract manufacturers and clinical study partners.
• Potential negative interactions between product candidates and other treatments.

Future Outlook

Data from Part 3 of the Phase 1 clinical trial is expected in the fourth quarter of 2026. The company is focused on demonstrating DA-1726's potential to deliver differentiated efficacy and a more streamlined path to optimal dosing.

Management Comments

• "Dosing the first patient in these higher-dose cohorts is an exciting milestone that moves us closer to unlocking the full potential of DA-1726."
• "We have already seen compelling results, including approximately 9% weight loss at the 48 mg dose, along with meaningful reductions in waist circumference, improved glycemic control, and early signals of direct liver benefit, all with a favorable tolerability profile."
• "We believe these results highlight the potential of our dual GLP-1/glucagon approach."
• "Importantly, Part 3 is designed to reach higher therapeutic doses with improved tolerability, which could represent a meaningful advantage compared to currently marketed therapies that require longer, more gradual titration."
• "With data expected in the fourth quarter of 2026, we are focused on further demonstrating DA-1726s potential to deliver differentiated efficacy and a more streamlined path to optimal dosing."

Industry Context

StockSavvy.ai notes that MetaVia's advancement of DA-1726 into higher-dose cohorts positions it within the highly competitive and rapidly growing obesity and cardiometabolic disease market, where dual-acting agonists are showing promise for improved efficacy and tolerability.

Comparison to Industry Standards

• In pre-clinical mouse models, DA-1726 showed improved weight loss compared to semaglutide (Wegovy).
• In pre-clinical mouse models, DA-1726 elicited similar weight reduction to tirzepatide (Zepbound) and survodutide, while consuming more food.
• DA-1726 demonstrated improved lipid-lowering effects compared to survodutide in pre-clinical models.
• The company aims for DA-1726 to offer a more streamlined path to optimal dosing compared to current therapies that require longer, more gradual titration.

Stakeholder Impact

• Shareholders: Positive impact from continued progress in clinical development of a potentially valuable drug candidate.
• Patients: Potential future benefit from a new treatment option for obesity and MASH.
• Healthcare Providers: Potential for a new therapeutic option with differentiated efficacy and tolerability.

Next Steps

• Complete enrollment of the 40 obese, otherwise healthy adult subjects in Part 3 of the Phase 1 trial.
• Evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726.
• Assess primary endpoints including adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation.
• Evaluate secondary and exploratory endpoints including metabolic, glycemic, lipid, and body composition measures.
• Generate and release data from Part 3 of the Phase 1 trial in the fourth quarter of 2026.

Key Dates

Recommendation

The company is making progress in its clinical trials, which is positive. However, the drug is still in Phase 1, and significant development and regulatory hurdles remain. While early data is encouraging, it is too soon to make a strong buy or sell recommendation. Holding allows investors to monitor further trial results and development milestones.

Keywords

DA-1726, Obesity, GLP-1 agonist, Glucagon agonist, Dual agonist, Phase 1 trial, Clinical trial, Biotechnology